*To be printed on hospital headed paper*

**PARTICIPANT INFORMATION SHEET (16+) – SUMMARY**

**rEECur**

**International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma**

**What is the rEECur trial?**

The aim of the rEECur trial is to compare different chemotherapy regimens to find out which is most effective and/or has fewest side effects.

**Why have I been invited to take part?**

You have been invited to participate in this trial because you have recently been diagnosed with Ewing sarcoma that has either not responded to initial treatment or has recurred after the end of treatment.

**What will I have to do?**

If you agree to participate, you will receive one of the available chemotherapy regimens: **CE** (carboplatin and etoposide) **or IFOS** (ifosfamide).

This study is "randomised" which means that what treatment you receive will be decided at random, like drawing lots. You will be scheduled to receive at least 4 (IFOS) or 6 (CE) cycles of that treatment, although if your disease responds well your doctor may choose to give you more. You will be asked to attend all scheduled clinic appointments and scans. You will also be asked to complete questionnaires about your quality of life on treatment.

**What are the possible disadvantages and risks of taking part?**

Your doctor will discuss any risks of participation with you.

**What are the possible benefits of taking part?**

We cannot promise that you will benefit from taking part in this study, although it is possible that the treatment arm that you are allocated to will be the most effective or have the fewest side effects. We will not know this until the results of the trial are available. The information gained from this study will help improve treatment for other children and adults with Ewing sarcoma in the future.

**Please note that you do not have to take part in this study if you do not want to. If you do decide to take part, you may withdraw at any time without giving a reason. This will not affect the standard of your medical care.**

If you would like more information on the study, please ask for a Participant Information Sheet.

*Thank you for reading this information sheet.*